1
|
Zappettini S, Faivre E, Ghestem A, Carrier S, Buée L, Blum D, Esclapez M, Bernard C. Caffeine Consumption During Pregnancy Accelerates the Development of Cognitive Deficits in Offspring in a Model of Tauopathy. Front Cell Neurosci 2019; 13:438. [PMID: 31680863 PMCID: PMC6797851 DOI: 10.3389/fncel.2019.00438] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Accepted: 09/13/2019] [Indexed: 01/12/2023] Open
Abstract
Psychoactive drugs used during pregnancy can affect the development of the brain of offspring, directly triggering neurological disorders or increasing the risk for their occurrence. Caffeine is the most widely consumed psychoactive drug, including during pregnancy. In Wild type mice, early life exposure to caffeine renders offspring more susceptible to seizures. Here, we tested the long-term consequences of early life exposure to caffeine in THY-Tau22 transgenic mice, a model of Alzheimer’s disease-like Tau pathology. Caffeine exposed mutant offspring developed cognitive earlier than water treated mutants. Electrophysiological recordings of hippocampal CA1 pyramidal cells in vitro revealed that early life exposure to caffeine changed the way the glutamatergic and GABAergic drives were modified by the Tau pathology. We conclude that early-life exposure to caffeine affects the Tau phenotype and we suggest that caffeine exposure during pregnancy may constitute a risk-factor for early onset of Alzheimer’s disease-like pathology.
Collapse
Affiliation(s)
- Stefania Zappettini
- Aix Marseille Univ, INSERM, INS, Institut de Neurosciences des Systèmes, Marseille, France
| | - Emilie Faivre
- Inserm, CHU Lille, LabEx DISTALZ, UMR-S 1172 - JPArc, Université de Lille, Lille, France
| | - Antoine Ghestem
- Aix Marseille Univ, INSERM, INS, Institut de Neurosciences des Systèmes, Marseille, France
| | - Sébastien Carrier
- Inserm, CHU Lille, LabEx DISTALZ, UMR-S 1172 - JPArc, Université de Lille, Lille, France
| | - Luc Buée
- Inserm, CHU Lille, LabEx DISTALZ, UMR-S 1172 - JPArc, Université de Lille, Lille, France
| | - David Blum
- Inserm, CHU Lille, LabEx DISTALZ, UMR-S 1172 - JPArc, Université de Lille, Lille, France
| | - Monique Esclapez
- Aix Marseille Univ, INSERM, INS, Institut de Neurosciences des Systèmes, Marseille, France
| | - Christophe Bernard
- Aix Marseille Univ, INSERM, INS, Institut de Neurosciences des Systèmes, Marseille, France
| |
Collapse
|
2
|
Martin E, Kanellopoulos J, Fontaine B, Delatour B, Delarasse C. Le récepteur P2X7, une nouvelle cible thérapeutique dans la maladie d’Alzheimer. Med Sci (Paris) 2019; 35:97-99. [DOI: 10.1051/medsci/2019017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|